JP2010518007A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010518007A5 JP2010518007A5 JP2009548329A JP2009548329A JP2010518007A5 JP 2010518007 A5 JP2010518007 A5 JP 2010518007A5 JP 2009548329 A JP2009548329 A JP 2009548329A JP 2009548329 A JP2009548329 A JP 2009548329A JP 2010518007 A5 JP2010518007 A5 JP 2010518007A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- polypeptide
- sema6a
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 80
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 68
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 51
- 229920001184 polypeptide Polymers 0.000 claims description 50
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 50
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 42
- 241000124008 Mammalia Species 0.000 claims description 37
- 102100032795 Semaphorin-6A Human genes 0.000 claims description 35
- 101710199479 Semaphorin-6A Proteins 0.000 claims description 35
- 230000006378 damage Effects 0.000 claims description 30
- 239000013598 vector Substances 0.000 claims description 30
- 201000010099 disease Diseases 0.000 claims description 28
- 210000004248 oligodendroglia Anatomy 0.000 claims description 23
- 208000027418 Wounds and injury Diseases 0.000 claims description 21
- 208000014674 injury Diseases 0.000 claims description 21
- 102000040430 polynucleotide Human genes 0.000 claims description 20
- 108091033319 polynucleotide Proteins 0.000 claims description 20
- 239000002157 polynucleotide Substances 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 14
- 230000001737 promoting effect Effects 0.000 claims description 14
- 230000004069 differentiation Effects 0.000 claims description 13
- 230000023105 myelination Effects 0.000 claims description 11
- 230000004083 survival effect Effects 0.000 claims description 11
- 102000001189 Cyclic Peptides Human genes 0.000 claims description 10
- 108010069514 Cyclic Peptides Proteins 0.000 claims description 10
- 201000006417 multiple sclerosis Diseases 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 10
- 208000012902 Nervous system disease Diseases 0.000 claims description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 8
- 208000016192 Demyelinating disease Diseases 0.000 claims description 7
- 206010012305 Demyelination Diseases 0.000 claims description 7
- 206010067601 Dysmyelination Diseases 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 7
- 210000002569 neuron Anatomy 0.000 claims description 6
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 6
- 230000001537 neural effect Effects 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000006386 Myelin Proteins Human genes 0.000 claims description 4
- 108010083674 Myelin Proteins Proteins 0.000 claims description 4
- 102100026784 Myelin proteolipid protein Human genes 0.000 claims description 4
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 206010047631 Vitamin E deficiency Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 230000030833 cell death Effects 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 201000002491 encephalomyelitis Diseases 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 210000005012 myelin Anatomy 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 241001529453 unidentified herpesvirus Species 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- 208000001738 Nervous System Trauma Diseases 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 210000000653 nervous system Anatomy 0.000 claims description 3
- 208000028412 nervous system injury Diseases 0.000 claims description 3
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 2
- 208000011403 Alexander disease Diseases 0.000 claims description 2
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 claims description 2
- 241000710929 Alphavirus Species 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 208000006373 Bell palsy Diseases 0.000 claims description 2
- 241000709661 Enterovirus Species 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims description 2
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims description 2
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 2
- 206010028570 Myelopathy Diseases 0.000 claims description 2
- 208000003435 Optic Neuritis Diseases 0.000 claims description 2
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 241000710778 Pestivirus Species 0.000 claims description 2
- 102100034381 Plexin-A2 Human genes 0.000 claims description 2
- 101710100258 Plexin-A2 Proteins 0.000 claims description 2
- 108010071390 Serum Albumin Proteins 0.000 claims description 2
- 102000007562 Serum Albumin Human genes 0.000 claims description 2
- 241000700584 Simplexvirus Species 0.000 claims description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 208000036826 VIIth nerve paralysis Diseases 0.000 claims description 2
- 241000700618 Vaccinia virus Species 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 206010073696 Wallerian degeneration Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 230000003458 metachromatic effect Effects 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 108010031345 placental alkaline phosphatase Proteins 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 208000009174 transverse myelitis Diseases 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241000701447 unidentified baculovirus Species 0.000 claims description 2
- 230000008734 wallerian degeneration Effects 0.000 claims description 2
- 210000004885 white matter Anatomy 0.000 claims description 2
- 230000024245 cell differentiation Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 57
- 241001465754 Metazoa Species 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89899207P | 2007-02-02 | 2007-02-02 | |
| US60/898,992 | 2007-02-02 | ||
| PCT/US2008/001444 WO2008097503A2 (en) | 2007-02-02 | 2008-02-04 | Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010518007A JP2010518007A (ja) | 2010-05-27 |
| JP2010518007A5 true JP2010518007A5 (enExample) | 2011-03-24 |
| JP5492567B2 JP5492567B2 (ja) | 2014-05-14 |
Family
ID=39682299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009548329A Active JP5492567B2 (ja) | 2007-02-02 | 2008-02-04 | 髄鞘形成およびオリゴデンドロサイト分化を促進するためのセマフォリン６ａの使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9107884B2 (enExample) |
| EP (1) | EP2114433B1 (enExample) |
| JP (1) | JP5492567B2 (enExample) |
| KR (1) | KR20090123873A (enExample) |
| CN (1) | CN101631559A (enExample) |
| AU (1) | AU2008214337B2 (enExample) |
| BR (1) | BRPI0806849A2 (enExample) |
| CA (1) | CA2677228C (enExample) |
| EA (1) | EA017403B1 (enExample) |
| GE (1) | GEP20135853B (enExample) |
| IL (1) | IL200123A (enExample) |
| MX (1) | MX2009008178A (enExample) |
| NZ (1) | NZ578816A (enExample) |
| SG (1) | SG178744A1 (enExample) |
| UA (1) | UA99452C2 (enExample) |
| WO (1) | WO2008097503A2 (enExample) |
| ZA (1) | ZA200905379B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8871205B2 (en) * | 2009-11-25 | 2014-10-28 | The University Of North Carolina At Chapel Hill | Methods and compositions for the treatment of immune disorders |
| US8986670B2 (en) * | 2012-02-29 | 2015-03-24 | Baxter International Inc. | IgG stimulated remyelination of peripheral nerves |
| RU2020109343A (ru) | 2014-11-05 | 2020-03-17 | Вояджер Терапьютикс, Инк. | Полинуклеотиды aadc для лечения болезни паркинсона |
| WO2016077687A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| CN112375760A (zh) | 2014-11-14 | 2021-02-19 | 沃雅戈治疗公司 | 调节性多核苷酸 |
| EP3262064A1 (en) * | 2015-02-23 | 2018-01-03 | Seagull Therapeutics SAS | Non-natural semaphorins 3 and their medical use |
| JP6924708B2 (ja) * | 2015-06-29 | 2021-08-25 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | Ｂ１ｓｐ融合タンパク質の治療薬、方法、および使用 |
| IL302748B1 (en) | 2016-05-18 | 2025-09-01 | Voyager Therapeutics Inc | Modulatory polynucleotides |
| JP7109040B2 (ja) * | 2016-07-25 | 2022-07-29 | 国立大学法人金沢大学 | 線維化抑制剤 |
| EP3618839A4 (en) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CA3099306A1 (en) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
| CN109536506B (zh) * | 2018-12-10 | 2022-03-22 | 潍坊科技学院 | 一种调控日本沼虾生长发育的类胰岛素受体基因及其应用 |
| KR20250075466A (ko) * | 2023-11-15 | 2025-05-28 | 주식회사 카인사이언스 | 탈수초 질환 치료용 펩타이드 및 이의 용도 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773319A (en) | 1971-12-16 | 1973-11-20 | Fabcor Ind Inc | Corrugated sheet inverting machine |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| EP0560410B1 (en) | 1987-04-27 | 2002-10-02 | Inverness Medical Switzerland GmbH | A test device for performing specific binding assays |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| ATE120454T1 (de) | 1988-06-14 | 1995-04-15 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
| JP2989002B2 (ja) | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | 化学修飾顆粒球コロニー刺激因子 |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| CA2078689C (en) | 1990-03-20 | 2003-02-11 | Sherie L. Morrison | Chimeric antibodies with receptor binding ligands in place of their constant region |
| US5219837A (en) * | 1990-06-21 | 1993-06-15 | Trustees Of The University Of Pennsylvania | Method of stimulating myelination of cells |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| DE69133036T2 (de) | 1990-11-09 | 2003-02-06 | Stephen D. Gillies | Cytokine immunokonjugate |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| EP0669986B1 (en) | 1992-11-13 | 2003-04-09 | Idec Pharmaceuticals Corporation | Fully impaired consensus kozac sequences for mammalian expression |
| US6068829A (en) | 1995-09-11 | 2000-05-30 | The Burnham Institute | Method of identifying molecules that home to a selected organ in vivo |
| RO120148B1 (ro) | 1997-03-14 | 2005-09-30 | Idec Pharmaceuticals Corporation | Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere |
| EP1365018A1 (en) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
| JP2005528434A (ja) * | 2002-05-30 | 2005-09-22 | キュラジェン コーポレイション | セマフォリン様タンパク質およびその使用方法 |
-
2008
- 2008-02-04 EA EA200901067A patent/EA017403B1/ru not_active IP Right Cessation
- 2008-02-04 AU AU2008214337A patent/AU2008214337B2/en not_active Ceased
- 2008-02-04 EP EP08713389.8A patent/EP2114433B1/en active Active
- 2008-02-04 CN CN200880003680A patent/CN101631559A/zh not_active Withdrawn
- 2008-02-04 US US12/525,514 patent/US9107884B2/en active Active
- 2008-02-04 CA CA2677228A patent/CA2677228C/en active Active
- 2008-02-04 WO PCT/US2008/001444 patent/WO2008097503A2/en not_active Ceased
- 2008-02-04 MX MX2009008178A patent/MX2009008178A/es active IP Right Grant
- 2008-02-04 SG SG2012007456A patent/SG178744A1/en unknown
- 2008-02-04 KR KR1020097018262A patent/KR20090123873A/ko not_active Ceased
- 2008-02-04 JP JP2009548329A patent/JP5492567B2/ja active Active
- 2008-02-04 NZ NZ578816A patent/NZ578816A/en not_active IP Right Cessation
- 2008-02-04 GE GEAP200811447A patent/GEP20135853B/en unknown
- 2008-02-04 UA UAA200908176A patent/UA99452C2/ru unknown
- 2008-02-04 BR BRPI0806849-6A patent/BRPI0806849A2/pt not_active Application Discontinuation
-
2009
- 2009-07-28 IL IL200123A patent/IL200123A/en active IP Right Grant
- 2009-07-31 ZA ZA2009/05379A patent/ZA200905379B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010518007A5 (enExample) | ||
| JP2009544703A5 (enExample) | ||
| US20240010708A1 (en) | Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods | |
| JP2011500566A5 (enExample) | ||
| Heitz et al. | Twenty years of cell‐penetrating peptides: from molecular mechanisms to therapeutics | |
| Chlebová et al. | High molecular weight FGF2: the biology of a nuclear growth factor | |
| US6531295B1 (en) | Synthetic constructs encoding syndecan | |
| JP5492567B2 (ja) | 髄鞘形成およびオリゴデンドロサイト分化を促進するためのセマフォリン６ａの使用 | |
| JP2021193112A (ja) | 生物学的に活性な特異的カーゴペプチドと結合したヒト由来の細胞透過性ペプチドの構造、製造および使用 | |
| JP2006507228A (ja) | 応答性の細胞、組織および器官を保護、回復ならびに増強するための組換え型組織保護サイトカインおよびそれをコードする核酸 | |
| Beerens et al. | Protein transduction domains and their utility in gene therapy | |
| CN104650210B (zh) | 作为体内造血刺激剂的tat‑hoxb4h重组蛋白质的制备方法 | |
| US6800286B1 (en) | Chimeric fibroblast growth factor proteins, nucleic acid molecules, and uses thereof | |
| EP2406281B1 (en) | Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity | |
| NZ568705A (en) | Methods for promoting neurite outgrowth and survival of dopaminergic neurons | |
| JP2009518299A5 (enExample) | ||
| CZ295997A3 (cs) | Způsob kultivace buněk | |
| CN1339068A (zh) | 转移核酸通过核被膜的细胞转运系统的用途 | |
| EP3263582B1 (en) | Polymer compound which has membrane-permeable peptide in side chain | |
| WO2007110079A2 (en) | Targeted delivery of fgfr ligands into the brain | |
| US20050069537A1 (en) | Survical promoting ncam binding and ncam ligand binding compounds | |
| WO2024054062A1 (ko) | 세포 내 형질주입을 위한 신규한 폴리펩타이드 조성물 | |
| US11472845B2 (en) | Antitumor peptide and use thereof | |
| WO2023229366A1 (en) | Surface-engineered extracellular vesicles and therapeutic uses thereof | |
| WO2025225980A1 (ko) | Nm3 돌연변이 adamts1 펩타이드 및 이를 포함하는 근육 질환 치료용 약제학적 조성물 |